Protocol Ledger

NCT07795346 · Phase III · RECRUITING

A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Interventional Phase III clinical trial protocol NCT07795346 sponsored by Antengene Biologics Limited in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-09-17 Enrollment: 380 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07795346
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)380 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07795346
Protocol FieldVerified Registry Value
NCT IdentifierNCT07795346
Consolidated Lead SponsorAntengene Biologics Limited
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment380 participants (ESTIMATED)
Registered Start Date2026-09-17
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI